DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2014/0315928A1 Darout Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2014/0315928A1 Darout Et Al US 201403 15928A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0315928A1 DarOut et al. (43) Pub. Date: Oct. 23, 2014 (54) SUBSTITUTEDAMIDE COMPOUNDS Publication Classification (71) Applicant: Pfizer Inc., New York, NY (US) (51) Int. Cl. C07D40 L/4 (2006.01) (72) Inventors: Etzer Darout, Cambridge, MA (US); A 6LX3/59 (2006.01) Robert Dullea, Groton, MA (US); Julie A6II 45/06 (2006.01) Jia Li Hawkins, Weston, CT (US); C07D 413/4 (2006.01) Allyn T. Londregan, Barrington, RI A613 L/437 (2006.01) (US); Paula M. Loria, Killingworth, CT A 6LX3L/24709 (2006.01) (US); Bruce Maguire, Chester, CT A613 L/4545 (2006.01) (US); Kim F. McClure, Mystic, CT C07D 487/04 (2006.01) (US); Donna N. Petersen, Salem, CT C07D 47L/04 (2006.01) (52) U.S. Cl. (US); David W. Piotrowski, Waterford, CPC ............ C07D401/14 (2013.01); C07D487/04 CT (US) (2013.01); A61 K3I/519 (2013.01); A61 K 45/06 (2013.01); C07D 471/04 (2013.01); (73) Assignee: Pfizer Inc., New York, NY (US) A6 IK3I/437 (2013.01); A61 K3I/4709 (2013.01); A61 K3I/4545 (2013.01); C07D 413/14 (2013.01) (21) Appl. No.: 14/253,084 USPC ........ 514/259.3:544/281: 546/117: 514/300; 546/143: 514/310:546/194; 514/318; 546/113 (22) Filed: Apr. 15, 2014 (57) ABSTRACT The present invention is directed at substituted amide com pounds, pharmaceutical compositions containing Such com Related U.S. Application Data pounds and the use of such compounds to reduce plasma lipid (60) Provisional application No. 61/812,864, filed on Apr. levels. Such as LDL-cholesterol and triglycerides and accord 17, 2013, provisional application No. 61/880,336, ingly to treat diseases which are exacerbated by high levels of filed on Sep. 20, 2013, provisional application No. LDL-cholesterol and triglycerides, such as atherosclerosis 61/898,667, filed on Nov. 1, 2013. and cardiovascular diseases, in mammals, including humans. Patent Application Publication Oct. 23, 2014 Sheet 1 of 10 US 2014/0315928A1 mixSN sawmar &N - frr as a was a SunOO) Patent Application Publication Oct. 23, 2014 Sheet 2 of 10 US 2014/0315928A1 15 Sa , S. - 8 - -- N rmera...a...a...ac. r ear {3 . D -P--- . c. 2ss: CN a -------- e -er--- --- - wer & tri-preppy-per-Trrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrl. c. c s c C C s d s d s r cy w (Sino) u" Patent Application Publication Oct. 23, 2014 Sheet 3 of 10 US 2014/0315928A1 3. s C C al d s Y CN (SunO) u" Patent Application Publication Oct. 23, 2014 Sheet 4 of 10 US 2014/0315928A1 ·{}{}{}A oooº ·{}{}{}{} door *oooº ºoooº |000?. (Suo) u Patent Application Publication Oct. 23, 2014 Sheet 5 of 10 US 2014/0315928A1 Patent Application Publication Oct. 23, 2014 Sheet 6 of 10 US 2014/0315928A1 (SLOC) u Patent Application Publication Oct. 23, 2014 Sheet 7 of 10 US 2014/0315928A1 Patent Application Publication Oct. 23, 2014 Sheet 8 of 10 US 2014/0315928A1 Patent Application Publication Oct. 23, 2014 Sheet 9 of 10 US 2014/0315928A1 {000'09 ?000’07 #000’o, Patent Application Publication Oct. 23, 2014 Sheet 10 of 10 US 2014/0315928A1 aaraaaaarara -----------Mr. ----- - referre --- reyers for first rrrr.Trri rty-fir r ---- (SunOO) u US 2014/03 15928A1 Oct. 23, 2014 SUBSTITUTEDAMIDE COMPOUNDS SUMMARY OF THE INVENTION CROSS-REFERENCE TO RELATED 0006. The present invention is directed to compounds of Formula I APPLICATION 0001. This application claims the benefit of priority of U.S. provisional Patent Application Ser. No. 61/812,864, Formula I filed Apr. 17, 2013: U.S. provisional Patent Application Ser. RI No. 61/880,336, filed Sep. 20, 2013 and U.S. provisional lo Patent Application Ser. No. 61/898,667 filed Nov. 1, 2013, HN1 No.1 which are incorporated herein by reference in their entirety for all purposes. N- als, BACKGROUND OF INVENTION R?-- || 0002 The present invention relates to substituted amide N compounds, pharmaceutical compositions containing Such R3 compounds and the use of Such compounds to treat cardio vascular disease including atherosclerosis, hyperlipidemia, or a pharmaceutically acceptable salt thereof wherein hypercholesterolemia, and hypertriglyceridemia in mam R" is pyrid-2-yl, isoquinolin-1-yl or 1H-pyrrolo[2.3-clpyri mals, including humans. din-7-yl; 0003 Atherosclerosis, a disease of the arteries, is recog R" is optionally mono- or di-substituted with chloro or (C- nized to be the leading cause of death in the United States and C.)alkyl: Western Europe. The pathological sequence leading to ath X and Y are independently either N or C(H), provided that at erosclerosis and occlusive heart disease is well known. The least one of X or Y is C(H): earliest stage in this sequence is the formation of “fatty R’ is H. fluoro, hydroxyl or methyl: streaks' in the carotid, coronary and cerebral arteries and in the aorta. These lesions are yellow in color due to the presence R is of lipid deposits found principally within Smooth-muscle cells and in macrophages of the intima layer of the arteries 0007 and aorta. Further, it is postulated that most of the cholesterol found within the fatty streaks, in turn, gives rise to develop ment of the “fibrous plaque,” which consists of accumulated intimal smooth muscle cells laden with lipid and surrounded by extra-cellular lipid, collagen, elastin and proteoglycans. These cells plus matrix form a fibrous cap that covers a deeper deposit of cell debris and more extracellular lipid. The lipid is primarily free and esterified cholesterol. The fibrous plaque forms slowly, and is likely in time to become calcified and necrotic, advancing to the “complicated lesion, which accounts for the arterial occlusion and tendency toward mural R O thrombosis and arterial muscle spasm that characterize N advanced atherosclerosis. NNN R7 0004 Epidemiological evidence has firmly established hyperlipidemia as a primary risk factor in causing cardiovas Yo cular disease (CVD) due to atherosclerosis. In recent years, leaders of the medical profession have placed renewed wherein Rand Rare each independently H. methyl, halo or emphasis on lowering plasma cholesterol levels, and low (C-C)alkyloxy, provided that only one of RandR is halo; density lipoprotein cholesterol in particular, as an essential wherein R'' and R'' are each independently H, (C-C)alkyl step in prevention of CVD. The upper limits of “normal are or (C-C)cycloalkyl, and now known to be significantly lower than heretofore appre wherein R is hydroxyl, (C-C)alkyloxy, (C-C)alkoxycar ciated. As a result, large segments of Western populations are bonyloxy(C-C)alkyloxy, or (C-C)alkylcarbonyloxy(C- now realized to be at particularly high risk. Additional inde C.)alkoxy. pendent risk factors include glucose intolerance, left ven 0008. The present application is also directed to methods tricular hypertrophy, hypertension, and being of the male sex. for treating dyslipidemia, hypercholesterolemia (including Cardiovascular disease is especially prevalent among dia heterozygous and homozygous familial hypercholester betic Subjects, at least in part because of the existence of olemia), hypertriglyceridemia, hyperlipidemia, hypoalphali multiple independent risk factors in this population. Success poproteinemia, metabolic syndrome, diabetic complications, ful treatment of hyperlipidemia in the general population, and atherosclerosis, stroke, Vascular dimensia, chronic kidney in diabetic subjects in particular, is therefore of exceptional disease, coronary heart disease, coronary artery disease, ret medical importance. inopathy, inflammation, thrombosis, peripheral vascular dis 0005 While there are a variety of anti-atherosclerosis ease or congestive heart failure in a mammal by administering compounds, cardiovascular disease is still a leading cause of to a mammal in need of Such treatment a therapeutically death and accordingly, there is a continuing need and a con effective amount of a compound of Formula I or a pharma tinuing search in this field of art for alternative therapies. ceutically acceptable salt of said compound. US 2014/03 15928A1 Oct. 23, 2014 0009. The present application also is directed to pharma R is ceutical compositions which comprise a therapeutically effective amount of a compound of Formula I, or a pharma 0017 ceutically acceptable salt of said compound and a pharma ceutically acceptable carrier, vehicle or diluent. 0010. In addition, the present application is directed to R8 N 4. pharmaceutical combination compositions comprising: a N n N therapeutically effective amount of a composition comprising 21 C s /N 0.011 a first compound, said first compound being a com N N/ R6 2N. pound of Formula I or a pharmaceutically acceptable salt of said compound; 0012 a second compound, said second compound being a R O R NN-" lipid modulating agent; and N Y (/ 0013 a pharmaceutically acceptable carrier, vehicle or R7 NNN 2N diluent. Yo 0014 Examples of lipid modulating agents include a R 14 lipase inhibitor, an HMG-CoA reductase inhibitor, an HMG CoA synthase inhibitor, an HMG-CoA reductase gene R O expression inhibitor, an HMG-CoA synthase gene expression s N st inhibitor, an MTP/Apo B secretion inhibitor, a CETP inhibi ( -N NNN) {N-O tor, a bile acid absorption inhibitor, a cholesterol absorption V inhibitor, a cholesterol synthesis inhibitor, a squalene Syn R10 thetase inhibitor, a squalene epoxidase inhibitor, a squalene cyclase inhibitor, a combined squalene epoxidase/squalene cyclase inhibitor, a fibrate, niacin, a combination of niacin R N O and lovastatin, an ion-exchange resin, an antioxidant, an R15 ACAT inhibitor and a bile acid sequestrant. NNN N1 V Y. 0015. Another aspect of this invention is directed to a R10 method of treating dyslipidemia by administering to a patient in need thereof a therapeutically effective amount of a com wherein RandR are each independently H, methyl, halo or pound that selectively inhibits the translation of PCSK9 (C-C)alkyloxy, provided that only one of RandR is halo; mRNA to PCSK9 protein.
Load more

Recommended publications
  • Activation of Diboron Reagents: the Development of Mild Conditions for the Synthesis of Unique Organoboron Compounds
    Activation of diboron reagents: The development of mild conditions for the synthesis of unique organoboron compounds Steven Brandon Thorpe Dissertation submitted to the faculty of the Virginia Polytechnic Institute and State University in partial fulfillment of the requirements for the degree of Doctor of Philosophy In Chemistry Webster L. Santos, Chairman Paul R. Carlier David G. I. Kingston James M. Tanko March 23, 2012 Blacksburg, Virginia Keywords: borylation, diboron reagent, boronic ester, conjugate addition, copper catalysis © 2012 by Steven B. Thorpe Activation of diboron reagents: The development of mild conditions for the synthesis of unique organoboron compounds Steven Brandon Thorpe ABSTRACT The first successful synthesis and isolation of a boronic acid was reported in 1860 by Frankland in the pursuit of novel organometallic compounds. For more than a century, further studies of boronic acids were sparsely published. Suzuki and Miyaura jumpstarted the field in 1979 with an innovative carbon-carbon bond forming reaction employing an organoboronic acid and a carbon halide under palladium catalysis. Indeed, the Nobel Prize in Chemistry was awarded to Professor Akira Suzuki, along with Professors Richard Heck and Ei-ichi Negishi, in 2010 for their important contributions in palladium-catalyzed cross-coupling chemistry. Over the last 30 years, reports on organoboron compounds have increased exponentially. This dissertation describes the author’s contributions to the development of preparative methods for organoboronic acid derivatives
    [Show full text]
  • ( 12 ) United States Patent
    US010618878B1 (12 ) United States Patent ( 10 ) Patent No.: US 10,618,878 B1 Shaikh et al. (45 ) Date of Patent : Apr. 14 , 2020 (54 ) CATALYTIC REDUCTION OF AROMATIC in Water ; ACS Sustainable Chemistry Energy 4 ( 3 ) ; pp . 1834-1839 ; RING IN AQUEOUS MEDIUM Feb. 16 , 2016 ; Abstract Only ; 2 Pages. Biswas , et al. , A Mild Rhodium Catalyzed Direct Synthesis of ( 71) Applicant: King Fahd University of Petroleum Quinolones from Pyridones : Application in the Detection ofNitroaromat and Minerals , Dhahran (SA ) ics ; The Journal of Organic Chemistry 82 ( 20 ) ; pp . 10989-10996 ; Sep. 13 , 2017 ; Abstract Only ; 2 Pages . (72 ) Inventors: M. Nasiruzzaman Shaikh , Dhahran Laska , et al .; Rhodium Containing Magnetic Nanoparticles: Effec (SA ) ; Zain H. Yamani, Dhahran (SA ) tive Catalysts for Hydrogenation and the 1,4 - Addition of Boronic Acids ; Catalysis Letters vol. 122 , Issue 1-2 ; pp . 68-75 ; Dec. 1 , 2007 ; (73 ) Assignee : King Fahd University of Petroleum Abstract Only ; 5 Pages . and Minerals , Dhahran (SA ) Shaikh , et al.; Sub -nanometric Rh decorated magnetic nanoparticles as reusable catalysts for nitroarene reduction in water ; Catalysis ( * ) Notice : Subject to any disclaimer , the term of this Communications vol . 119 ; pp . 134-138 ; Jan. 10 , 2019 ; Abstract patent is extended or adjusted under 35 Only ; 2 Pages . U.S.C. 154 ( b ) by 0 days. Baralt, et al .; Homogeneous Catalytic Hydrogenation . 6. Synthetic and Mechanistic Aspects of the Regioselective Reductions ofModel ( 21) Appl. No .: 16 /366,586 Coal Nitrogen , Sulfur, and Oxygen Heteroaromatic Compounds Using the ( ~ 5 Pentamethylcyclopentadienyl )rhodiu?m ris( acetonitrile ) ( 22 ) Filed : Mar. 27 , 2019 Dication Complex as the Catalyst Precursor ; J.
    [Show full text]
  • Program Book.PDF
    16th Boron Chemistry Meeting in the Americas June 26 - 30, 2018 at Boston College Program and Abstracts 1 WELCOME It is our distinct pleasure to welcome you to the 16th Boron Chemistry Meeting in the Americas here at Boston College. We hope that you will enjoy the historic city of Boston as well as the four-day program filled with exciting talks and stimulating discussions. Delegates from all over the world (North-, Central-, and South America, Europe, and Asia), and from diverse backgrounds (academia, industry, and government) are coming together at this conference to learn about the latest developments in boron chemistry. Thus, we hope that this gathering will not only promote scientific exchange and collaboration but also provide an opportunity for participants to make new connections and to reconnect with old friends. In organizing the program, the vision we had was to highlight the versatility of the element boron in four specific areas (medicinal chemistry, organic synthesis, materials chemistry, fundamental chemistry). This four-pronged thematic focus is represented by our conference logo with four infinity symbols surrounding the boron and is reflected by the scientific program. One of the highlights of the program will be the poster session on Wednesday evening. This will be a great opportunity to chat about the latest research while enjoying small bites and drinks. Another highlight is the conference banquet, which will take place on Thursday evening at the exquisite State Room with unparalleled views of the city and the Boston waterfront from the 33rd floor in the heart of downtown Boston. During the banquet we will celebrate Prof.
    [Show full text]
  • Palladium-Catalyzed Synthesis and Transformation of Organoboranes
    Palladium-Catalyzed Synthesis and Transformation of Organoboranes Sara Sebelius Stockholm University Department of Organic Chemistry August 2006 © Sara Sebelius, Stockholm 2006 ISBN 91-7155-290-1 Typesetting: AB Danagårds Grafiska, Ekonomi-Print Krokodilen Printed in Sweden by AB Danagårds Grafiska, Ekonomi-Print Krokodilen, Stockholm 2006 Distributor: Stockholm University Library ii Till Helen iii iv Abstract This thesis presents the development of new palladium-catalyzed transformations involving synthesis and application of allylborane reagents. In these reactions various palladium sources, including pincer complexes and commonly used catalysts were applied. A new transformation for allylation of aldehyde and imine substrates was devised using allyl acetates, diboronate reagents and catalytic amounts of Pd2(dba)3. By employment of commercially available chiral diboronates enantioenriched homoallyl alcohols could be obtained. We have also developed a palladium-catalyzed method for synthesis of functionalized allylboronic acids from vinyl cyclopropane, vinyl aziridine, allyl acetate and allyl alcohol substrates using diboronic acid as reagent. In this process a highly selective selenium based pincer- complex was used as catalyst. The resulting allylboronic acid products were converted to potassium trifluoro(allyl)borates or allylboronates. The functionalized allylboronic acids generated in the above procedure were employed as reagents in two synthetic transformations. One of these transformations involves a palladium(0)-catalyzed coupling reaction between allylboronic acids and aryl iodides. The reaction was regioselective for the branched allylic product, typically difficult to prepare in the absence of directing groups. We also developed another transformation for allylation of aldehydes with allyl alcohols via allylboronic acid intermediate. This procedure can be performed as a simple one-pot sequence affording homoallyl alcohols with excellent stereo- and regioselectivity.
    [Show full text]
  • WO 2014/170786 Al 23 October 2014 (23.10.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/170786 Al 23 October 2014 (23.10.2014) P O P C T (51) International Patent Classification: 06419 (US). MAGUIRE, Bruce; 17 Waterhouse Lane, C07D 401/14 (2006.01) C07D 471/04 (2006.01) Chester, Connecticut 06412 (US). MCCLURE, Kim F.; C07D 413/14 (2006.01) C07D 487/04 (2006.01) 12 Willow Drive, Mystic, Connecticut 06355 (US). A61K 31/4725 (2006.01) A61P 7/00 (2006.01) PETERSEN, Donna N.; 107 Forsyth Road, Salem, Con A61K 31/519 (2006.01) necticut 06420 (US). PIOTROWSKI, David W.; 19 Beacon Hill Drive, Waterford, Connecticut 06385 (US). (21) International Application Number: PCT/IB20 14/060407 (74) Agent: OLSON, A. Dean; Pfizer Inc., Eastern Point Road MS8260-2141, Groton, CT 06340 (US). (22) International Filing Date: 3 April 2014 (03.04.2014) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (25) Filing Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (26) Publication Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 61/812,864 17 April 2013 (17.04.2013) US KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/880,336 20 September 2013 (20.09.2013) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 61/898,667 1 November 2013 (01.
    [Show full text]
  • Aldrichimica Acta 48.1
    VOL. 48, NO. 1 • 2015 GREEN CHEMISTRY ISSUE • B. H. LIPSHUTZ, GUEST EDITOR CONTRIBUTORS TO THIS ISSUE Anastas • Constable • Gallou and Hamann • Gladysz • Jessop • Koenig • Krische • Lipshutz • Ritter • Stahl • Tucker • Warner ADDITIONAL ONLINE CONTRIBUTORS Rogers • Sheldon TABLE OF CONTENTS Paul T. Anastas: Green Chemistry Next: Moving from Evolutionary Philip G. Jessop: Switchable Solvents as Media for Synthesis to Revolutionary . .3 and Separations . 18 Stephen K. Ritter: Taking a Measure of Green Success . 5 Stefan G. Koenig*, Marian C. Bryan, and Kristi L. Budzinski: David J. C. Constable: Moving Toward a Green Chemistry and The Leading Edge of Green Chemistry at Genentech . .22 Engineering Design Ethic . .7 Bruce H. Lipshutz* and Subir Ghorai: Green Chemistry in the Kelsey C. Miles and Shannon S. Stahl*: Practical Aerobic Alcohol Introductory Organic Laboratory . .23 Oxidation with Cu/Nitroxyl and Nitroxyl/NOx Catalyst Systems. .8 Tathagata Mukherjee and John A. Gladysz*: Fluorous Chemistry Fabrice Gallou and Lawrence G. Hamann: Toward a Sustainability Meets Green Chemistry: A Concise Primer. 25 Mindset in the Practice of Pharmaceutical Chemistry—from John C. Warner: Where We Should Focus Green Chemistry Efforts . 29 Early Discovery to Manufacturing . .12 Inji Shin, T. Patrick Montgomery, and Michael J. Krische*: Additional Online Contributors Catalytic C–C Bond Formation and the Hendricksonian Ideal: Atom- and Steven P. Kelley and Robin D. Rogers*: A Practical Overview of Redox-Economy, Stereo- and Site-Selectivity . 15 Organic Synthesis in Ionic Liquids . Aldrich.com/acta John L. Tucker: Pharmaceutical Green Chemistry at Amgen: Roger A. Sheldon: Biocatalysis and Biomass Conversion Seeing with New Eyes . 16 in Ionic Liquids .
    [Show full text]
  • Diboron(4) Compounds: from Structural Curiosity to Synthetic Workhorse Emily C
    This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes. Review pubs.acs.org/CR Diboron(4) Compounds: From Structural Curiosity to Synthetic Workhorse Emily C. Neeve,† Stephen J. Geier,§ Ibraheem A. I. Mkhalid,‡ Stephen A. Westcott,*,§ and Todd B. Marder*,† † Institut für Anorganische Chemie, Julius-Maximilians-UniversitatWü ̈rzburg, Würzburg 97074, Germany § Mount Allison University, Department of Biochemistry and Chemistry, Sackville, New Brunswick E4L 1G8, Canada ‡ Department of Chemistry, King Abdulaziz University, Jeddah 21413, Saudi Arabia ABSTRACT: Although known for over 90 years, only in the past two decades has the chemistry of diboron(4) compounds been extensively explored. Many interesting structural features and reaction patterns have emerged, and more importantly, these compounds now feature prominently in both metal-catalyzed and metal-free methodologies for the formation of B−C bonds and other processes. CONTENTS 4. Boryl Addition (Hydroboration) Reactions 9115 4.1. α,β-Unsaturated Carbonyls, Imines, and 1. Introduction 9092 Related Compounds 9115 2. Synthesis, Structure, and Bonding of Diboron(4) 4.2. Alkynes 9119 Compounds 9093 4.3. Alkenes 9121 2.1. B2X4 Compounds 9093 4.4. Dienes, Enynes, and Allenes 9122 2.2. B2H4 Chemistry 9094 4.5. Aldehydes and Imines 9123 2.3. B2(NR2)4 Compounds 9094 4.6. Ring-Opening Reactions 9123 2.4. B2(alkyl)n Compounds 9095 4.7. Borylative Cyclizations and Related Intermo- 2.5. B2(OR)4 Compounds 9095 lecular Reactions 9124 2.5.1. Synthesis of B2(OR)4 9095 4.8.
    [Show full text]
  • Scienza Del Farmaco E Delle Sostanze Bioattive”
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Electronic Thesis and Dissertation Archive - Università di Pisa UNIVERSITY OF PISA School of Graduate Studies “Scienza del Farmaco e delle Sostanze Bioattive” PhD THESIS 2008-2010 “Development of novel regio- and stereoselective ring opening of heterocyclic compounds” SSD: CHIM06 Stefano Crotti SUPERVISOR DIRECTOR OF THE SCHOOL Prof. Mauro Pineschi Prof. Claudia Martini 2011 Index Index Chapter 1 Bicyclic oxazines 1.1 Introduction 1 1.1.1 Bicyclic oxazine 1 1.1.2 Asymmetric Hetero Diels-Alder cycloadducts 3 1.1.3 Regio- and stereo- selective ring opening of bicyclic oxazines with O-nucleophiles 5 1.1.4 Regio- and stereo- selective ring opening of bicyclic oxazines with C-nucleophiles 11 1.1.5 Rearrangement reaction 18 1.2 Results and discussion 21 1.2.1 Copper-catalyzed ring-opening of [2.2.2]acylnitroso cycloadducts 21 1.2.2 Rearrangement reaction 30 1.3 Experimental section 36 1.4 Bibliography 44 Chapter 2 Metal-catalyzed desymmetrization of diaza bicyclic alkenes with carbon nucleophiles 2.1 Introduction 45 2.1.1 Nucleophilic ring-opening of diazabicyclic system 45 2.1.2 Rearrangement reaction 52 2.2 Results and discussion 55 2.2.1 Rhodium-catalyzed ring-opening reaction of diaza bicyclic systems 55 2.2.2 Copper-catalyzed rearrangement and ring-opening reaction of diaza bicyclic 64 systems 2.3 Experimental section 70 2.4 Bibliography 90 Chapter 3 Nickel-Catalyzed Borylative Ring Opening of Vinyl Epoxides and Aziridines 3.1 Introduction 91 3.1.1 Bis(pinacolato)diboron
    [Show full text]
  • Palladium-Catalyzed Borylation and Cross-Coupling of Aryl and Heteroaryl Halides Utilizing Dibora Derivatives
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2012 Palladium-Catalyzed Borylation And Cross-Coupling Of Aryl And Heteroaryl Halides Utilizing Dibora Derivatives Sarah Little Jane Trice University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Organic Chemistry Commons Recommended Citation Trice, Sarah Little Jane, "Palladium-Catalyzed Borylation And Cross-Coupling Of Aryl And Heteroaryl Halides Utilizing Dibora Derivatives" (2012). Publicly Accessible Penn Dissertations. 712. https://repository.upenn.edu/edissertations/712 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/712 For more information, please contact [email protected]. Palladium-Catalyzed Borylation And Cross-Coupling Of Aryl And Heteroaryl Halides Utilizing Dibora Derivatives Abstract ABSTRACT PALLADIUM-CATALYZED BORYLATION AND CROSS-COUPLING OF ARYL AND HETEROARYL HALIDES UTILIZING DIBORA DERIVATIVES Sarah Little Jane Trice Professor Gary A. Molander Although much current research focuses on developing new boron reagents and identifying robust catalytic systems for the cross-coupling of these reagents, the fundamental preparations of the nucleophilic partners (i.e., boronic acids and derivatives) has been studied to a lesser extent. Most current methods to access boronic acids are indirect and require harsh conditions or expensive reagents. Therefore, we sought to provide a simple, efficient, and direct synthesis of arylboronic acids. Utilizing aryl halides and an underutilized reagent, tetrahydroxydiboron B2(OH)4, we developed a palladium-catalyzed method that now provides access to boronic acids in high yield. The method eliminates the necessity to employ the extremely wasteful and most commonly used source of boron, bis(pinacolato)diboron.
    [Show full text]
  • Synthesis, Characterization, and Reactions of Selected Heteronuclear Diboron Ring Systems
    This dissertation has been microfilmed exactly as received 66-15,151 W E L C H , Cletus Norman, 1937- SYNTHESIS, CHARACTERIZATION, AND REACTIONS OF SELECTED HETERONUCLEAR DIBORON RING SYSTEMS, The Ohio State University, Ph.D., 1966 Chemistry, inorganic University Microfilms, Inc., Ann Arbor, Michigan SYNTHESIS, CHARACTERIZATION, AND REACTIONS OF SELECTED HETERONUCLEAR DIBORON RING SYSTEMS DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Cletus Norman Welch, B.S., M.Sc, The Ohio State University 1966 Approved by Adviser Department of Chemistry ACKNOWLEDGMENTS This investigation was financially supported by a grant from the National Science Foundation. I would like to take this opportunity to express my appreciation to Dr. Sheldon G„ Shore for his continued interest and guidance throughout the duration of this investigation and in the preparation of this dissertation. A special note of thanks goes to my colleagues Mr. Russell A. Geanangel, Mr. David E. Young, and Dr. Roger K. Bunting for their generous imparting of beneficial assistance, equipment, and technical information. My wife, Delores, deserves a sincere expression of appreciation for her unselfish desires, understanding, and moral support to the completion of this investigation, 11 VITA February 2, 1937 Born— Convoy , Ohio 1 9 6 1 ............ B.S., Bowling Green State University, Bowling Green, Ohio 1961-1954. Teaching Assistant, Department of Chemistry, The Ohio State University, Columbus, Ohio 1964 ............ M. Sc., The Ohio State University, Columbus, Ohio 1964-1966. Research Fellow, Department of Chemistry, The Ohio State University, Columbus, Ohio PUBLICATIONS "New Organic Boron Heterocycles Contain Oxygen or Sulfur Atoms in the Ring," C & EN News, p.
    [Show full text]
  • Preparation and Lewis Acid Properties of Diboron Tetrafluoride and Related Compounds
    AN ABSTRACT OF THE THESIS OF JOHN DONALD HANSEN for the Ph. D. in Inorganic Chemistry (Name) (Degree) (Major) Date thesis is presented February 1, 1965 Title PREPARATION AND LEWIS ACID PROPERTIES OF DIBORON TETRAFLUORIDE AND RELATED COMPOUNDS Abstract approved (Major professor) Attempts to synthesize diboron tetrafluoride by the reduction of boron trifluoride with alkali metal solutions in 1, 2 - dimethoxyethane proved to be unsuccessful. No diboron tetrahalide was found when boron trifluoride, antimony trifluoride, or boron trichloride was reacted with tetra -(dimethylamino) - diboron; although there appeared to be some exchange between chloride and amine groups. Diboron tetrafluoride was prepared by the treatment of diboron tetrachloride with antimony trifluoride. The diboron tetrachloride was produced by the acid hydrolysis of tetra -(dimethylamino) -diboron to hypoboric acid with subsequent dehydration and reaction with boron trichloride. From the results of.the formation of Lewis acid -base complexes and their acid displacement reactions the order of relative acid strength was found to be: hydrogen chloride, diboron tetrafluoride boron trifluoride <boron trichloride. Diboron tetrafluoride formed strong complexes with triethylamine, trimethylamine, 2 , 6- lutidine, N, N, N', N' -tetramethylethylenediamine, and 1, 2- dimethoxyethane. A weak complex occurred with benzoni- trile, whereas, no complexation was found with p- chlorobenzonitrile. Boron trifluoride displaced diboron tetrafluoride from its complexes with 1, 2- dimethoxyethane, trimethylamine, and triethylamine. No displacement occurred, under the conditions investigated, with the complexes of N, N, N', N'- tetramethylethylenediamine and benzonitrile. It was found that p- chlorobenzonitrile serves as an excellent Lewis base for the separation of boron trifluoride from hydrogen chloride and boron trichloride impurities by complex formation.
    [Show full text]
  • United States Patent (10) Patent No.: US 9.227.956 B2 Darout Et Al
    US009227956B2 (12) United States Patent (10) Patent No.: US 9.227.956 B2 DarOut et al. (45) Date of Patent: Jan. 5, 2016 (54) SUBSTITUTEDAMIDE COMPOUNDS 8,283,116 B1 10/2012 Bhattacharyya et al. 8,329,667 B2 12/2012 Christiano (71) Applicant: Pfizer Inc., New York, NY (US) 2002/O1277O2 A1 9, 2002 Bernstein et al. 2003, OO321.58 A1 2/2003 Peltz et al. (72) Inventors: Etzer Darout, Cambridge, MA (US); 2003/0087852 Al 5/2003 DeBenedetti et al. Robert Dullea,r Groton,s MA (US);s Julie 2004/022492003 0119017. 12 A1A 11/20046/2003 McSwiggenDobie et al. Jia Li Hawkins, Weston, CT (US); 2005/00 19808 A1 1/2005 Palmenberg et al. Allyn T. Londregan, Barrington, RI 2005, 0164970 A1 T/2005 L (US); Paula M. Loria, Killingworth, CT 2005/0282849 A1 12/2005 Moon et al. (US); Bruce Maguire, Chester, CT 2006/0035212 A1 2/2006 Balakireva (US); Kim F. McClure, Mystic, CT 2006, O110397 A1 5.2006 Kim (US); Donna N. Petersen, Salem, CT 2007/0105764 A1 5/2007 Cosson et al. (US); David W. Piotrowski, Waterford, 2007/0281992 A1 12/2007 Batts et al. CT (US) 2008, OOO8697 A1 1/2008 Mintier et al. 2008, OO394.15 A1 2/2008 Stewart et al. 2008/0081791 A1 4/2008 Huang et al. (73) Assignee: Pfizer Inc., New York, NY (US) 2008/0260854 A1 10, 2008 Walker et al. (*) Notice: Subject to any disclaimer, the term of this SC A. S. S. patent is extended or adjusted under 35 2010, O158858 A1 6, 2010 C 1 U.S.C.
    [Show full text]